BridgeBio Pharma (BBIO)
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
Reports First Quarter 2026 Results
FLS awarded DKK 300 million order to supply key technologies for a BHQ iron ore beneficiation project in South Asia
Register of shareholders, changes and capital status – redemption of BONDS following buybacks of series 12, 13 and 14
Self-purchase/sale of securities
Dormant shares - creation of dormant shares
Appointment of Arava Paz Sevilia as CEO of Zephyros as of 22.7.26
Dormant shares – change in the number of shares
Net Asset Value(s)
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares